Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 895,833 |
|
|||||
| News | - | ||||||
| Day High | 4.85 | Low High |
|||||
| Day Low | 3.68 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Zura Bio Ltd | ZURA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 1.05 | 29.01% | 4.67 | 17:25:34 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.68 | 3.68 | 4.85 | 4.41 | 3.62 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 7,231 | 895,833 | $ 4.39 | $ 3,937,053 | - | 2.00 - 14.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 17:25:24 | 57 | $ 4.46 | USD |
Zura Bio Ltd Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 191.81M | 43.59M | - | 0 | -69.24M | -1.59 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Zura Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ZURA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.65 | 4.85 | 3.13 | 3.39 | 327,961 | 1.02 | 27.95% |
| 1 Month | 2.45 | 4.85 | 2.4157 | 3.26 | 269,936 | 2.22 | 90.61% |
| 3 Months | 3.14 | 4.85 | 2.00 | 2.91 | 303,146 | 1.53 | 48.73% |
| 6 Months | 5.35 | 5.50 | 2.00 | 3.51 | 245,270 | -0.68 | -12.71% |
| 1 Year | 7.88 | 14.00 | 2.00 | 5.95 | 339,276 | -3.21 | -40.74% |
| 3 Years | 8.00 | 37.55 | 2.00 | 7.85 | 338,945 | -3.33 | -41.63% |
| 5 Years | 8.00 | 37.55 | 2.00 | 7.85 | 338,945 | -3.33 | -41.63% |
Zura Bio Description
| Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California. |
